Marty Makary

Yeah.

Okay.

Okay.

That wasn't one that bothered me.

That wasn't one that bothered me.

Let's talk about the adult population.

Let's talk about the adult population.

I think 40 to 60%, depending on how you measure it, are clinically obese in this country.

I think 40 to 60%, depending on how you measure it, are clinically obese in this country.

And these incretin memetics, GLP-1 drugs and others, have really taken the market by storm, taken our population by storm.

And these incretin memetics, GLP-1 drugs and others, have really taken the market by storm, taken our population by storm.

So I realize that much of this is in response to an obesity epidemic that we're facing in this country.

So I realize that much of this is in response to an obesity epidemic that we're facing in this country.

But it turns out that these incretin memetics may actually have other systemic benefits.

But it turns out that these incretin memetics may actually have other systemic benefits.

And they're now, I think there's 60 indications that they're being tested against, including kidney, neurological, cardiac.

And they're now, I think there's 60 indications that they're being tested against, including kidney, neurological, cardiac.

I mean, there seems to be a lot of benefit potentially in using them for other disease indications.

I mean, there seems to be a lot of benefit potentially in using them for other disease indications.

Can you speak a little bit about your view on where this market, where this class of therapeutics is headed?